• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
ZHU Bao, JIN Shuanglong, GUO Yi, LI Yuezhen, ZHANG Yihua, LAI Yisheng. Design, synthesis and biological evaluation of pyridine-based IRAK4 inhibitors[J]. Journal of China Pharmaceutical University, 2017, 48(6): 670-674. DOI: 10.11665/j.issn.1000-5048.20170606
Citation: ZHU Bao, JIN Shuanglong, GUO Yi, LI Yuezhen, ZHANG Yihua, LAI Yisheng. Design, synthesis and biological evaluation of pyridine-based IRAK4 inhibitors[J]. Journal of China Pharmaceutical University, 2017, 48(6): 670-674. DOI: 10.11665/j.issn.1000-5048.20170606

Design, synthesis and biological evaluation of pyridine-based IRAK4 inhibitors

More Information
  • Based on the known IRAK4 inhibitors MK-32 and AU-5, we designed and synthesized 12 pyridine-based target compounds by adopting open-ring and hybrid strategies, and combining molecular docking technology. The bioassays determined by radioisotope labeling demonstrated that the target compounds displayed good inhibitory activity against IRAK4. Among them, the IC50 value of 5 compounds was less than 1 μmol/L, suggesting that these compounds may be candidates for further investigation.
  • [1]
    Li S,Strelow A,Fontana EJ,et al.H.IRAK-4:a novel member of the IRAK family with the properties of an IRAK-kinase [J].Proc Natl Acad Sci,2002,99(8):5567-5572.
    [2]
    Takeda K,Akira S.TLR signaling pathways[J].Semin Immunol,2004,16(1):3-9.
    [3]
    Suzuki N,Suzuki S,Duncan GS,et al.Severe impairment of interleukin-1 and Toll-like receptor signalling in mice lacking IRAK4[J].Nature, 2002,416(6882):750-756.
    [4]
    Ngo VN,Young RM,Schmitz R,et al.Oncogenically active MYD88 mutations in human lymphoma[J].Nature,2011,470(7332):115-119.
    [5]
    Yang,G,Zhou Y,Liu X,et al.A mutation in MYD88(L265P)supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia[J].Blood,2013,122(7):1222-1232.
    [6]
    Chaudhary D,Robinson S,Romero DL.Recent advances in the discovery of small molecule inhibitors of interleukin-1 receptor-associated kinase 4(IRAK4)as a therapeutic target for inflammation and oncology disorders[J].J Med Chem,2015,58(1):96-110.
    [7]
    Anastassiadis T,Deacon SW,Devarajan K,et al.Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity[J].Nat Biotechnol,2011,29(11):1039-1045.

Catalog

    Article views (1114) PDF downloads (1569) Cited by()

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return